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Abstract 
Cardiogenic shock which corresponds to an acute state of circulatory failure due to impairment of myocardial 
contractility is a very rare disease in children, even more than in adults. To date, no international recommendations 
regarding its management in critically ill children are available. An experts’ recommendations in adult population have 
recently been made (Levy et al. Ann Intensive Care 5(1):52, 2015; Levy et al. Ann Intensive Care 5(1):26, 2015). We pre‑
sent herein recommendations for the management of cardiogenic shock in children, developed with the grading of 
recommendations’ assessment, development, and evaluation system by an expert group of the Groupe Francophone 
de Réanimation et Urgences Pédiatriques (French Group for Pediatric Intensive Care and Emergencies). The recom‑
mendations cover four major fields of application such as: recognition of early signs of shock and the patient pathway, 
management principles and therapeutic goals, monitoring hemodynamic and biological variables, and circulatory 
support (indications, techniques, organization, and transfer criteria). Major principle care for children with cardiogenic 
shock is primarily based on clinical and echocardiographic assessment. There are few drugs reported as effective in 
childhood in the medical literature. The use of circulatory support should be facilitated in terms of organization and 
reflected in the centers that support these children. Children with cardiogenic shock are vulnerable and should be 
followed regularly by intensivist cardiologists and pediatricians. The experts emphasize the multidisciplinary nature of 
management of children with cardiogenic shock and the importance of effective communication between emer‑
gency medical assistance teams (SAMU), mobile pediatric emergency units (SMUR), pediatric emergency depart‑
ments, pediatric cardiology and cardiac surgery departments, and pediatric intensive care units.
© 2016 Brissaud et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Cardiogenic shock is an acute state of circulatory failure 
due to impairment of myocardial contractility. In chil-
dren, the clinical signs of cardiac failure are tachycardia, 
dyspnea, and hepatomegaly, together with global signs 
related to a decrease of cardiac output. Cardiogenic shock 
represents 5–13 % of diagnosed cases of shock in pediat-
ric emergencies [3, 4]. It is the most advanced and most 
serious stage of heart failure. In hospitalized children, 
cardiogenic shock is lethal in 5–10 % of cases, a mortality 
rate similar to that observed in adults [5, 6]. Extracardiac 
comorbidities (such as sepsis, acute kidney failure, and 
liver failure) can lead to a fivefold increase of the mortal-
ity rate [5, 6]. The following causes of heart failure are the 
most likely to lead to cardiogenic shock [5–10]: primary 
or secondary cardiomyopathy, acute or fulminant myo-
carditis, arrhythmia, congenital heart disease (whether 
surgically managed or not), postoperative period after 
cardiac surgery, and, in exceptional cases, endocardi-
tis, rheumatic fever, severe Kawasaki disease, stress car-
diomyopathy (Tako-Tsubo), valve cord rupture, drug or 
toxic substance intoxication. Cardiogenic shock can also 
be caused by extracardiac diseases (sepsis-induced myo-
cardial failure, pulmonary embolization, pneumothorax, 
tamponade). Mortality is directly related to the underly-
ing disease: congenital heart disease, rhythm disorders, 
acquired heart diseases, and cardiomyopathies, in 4.7, 23, 
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8.7, and 25 % of children, respectively [8, 11]. Mortality in 
case of decompensation is similar in children and adults. 
This is related to the fact that children also have other 
comorbidities but different from those of adults.
Management and monitoring of cardiogenic shock in 
childhood differ between anatomically normal heart and 
congenital heart disease. Recommendations made in this 
document are addressed to children without congenital 
heart disease; it is important in the case of children with 
heart disease who decompensates to be in contact with pedi-
atric cardiologists to optimize management. Cardiogenic 
shock occurs when heart and circulation are no longer able 
to adapt to the situation and is characterized by  severely 
impaired myocardial contractility, increased preload, 
severely impaired myocardial compliance, increased after-
load, and an abnormally and persistently high heart rate. 
Decompensation may occur and manifests as a drop in blood 
pressure and/or cardiac output with inadequate tissue perfu-
sion, as this is the final goal of cardiovascular performance, 
and the onset of anaerobic metabolism with the production 
of lactic acid. Unless treated, cardiogenic shock leads to mul-
tiple organ failure then progresses rapidly to death.
Even if the literature is poor regarding strong evidences 
in management of cardiogenic shock, we report, in this 
article, recommendations built by pediatricians and anes-
thesiologists, experts in the topic of cardiogenic shock. 
Process of recommendations’ elaboration permitted us 
to avoid making the recommendations only based on 
own experience. The recommendations cover four major 
fields of application such as: recognition of the early signs 
of shock and the patient pathway, management principles 
and therapeutic goals, monitoring hemodynamic and 
biological variables, and circulatory support (indications, 
techniques, organization, and transfer criteria).
Field of application 1: recognizing the early signs 
of shock
Three pathophysiological states have been described for 
cardiogenic shock (Fig. 1):
Cold and wet: reduced myocardial contractility and 
increased left ventricular filling pressure (systolic and 
diastolic dysfunction).
Cold and dry: reduced myocardial contractility and low 
left ventricular filling pressure (systolic dysfunction).
Warm and wet: normal myocardial contractil-
ity and high left ventricular filling pressure (diastolic 
dysfunction).
Clinical signs (Table 1)
Impaired consciousness, arterial hypotension, and respir-
atory distress with a fall in oxygen saturation are the early 
signs of decompensated heart failure and cardiogenic 
shock [12–14].
Etiological signs
Such signs are based on the patient’s medical/surgical history 
(heart disease, systemic disease, long-term heart failure), but 
also on blood pressure measurements in all limbs, as well as 
the presence of heart murmur, arrhythmia, or sepsis.
Fig. 1 Cardiogenic shock—Warner Stevenson concept (2)
Table 1 Nonspecific clinical signs of  cardiogenic shock 
in children
General Default weight gain, asthenia
Whiteness, sweating (diaphoresis) marbling ends
Hemodynamics Tachycardia, edema
Decreased peripheral pulses
Heart murmur, gallop rhythm
Bradycardia, arrhythmia
Jugular turgor
Respiratory Polypnea or bradypnea; crackles








Food difficulties (polypnea, sweating during feeding)
Kidney Oliguria
Anuria
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Para‑clinical signs
Chest X-rays (cardiomegaly, pulmonary edema), ECGs 
(arrhythmia, myocardial ischemia, conduction disorders, 
drugs effect, changes in the QT interval), and transtho-
racic echocardiograms are useful for diagnostic, etiologi-
cal, therapeutic, and prognostic purposes.
Complications
In addition to the risk of multiple organ failure and death, 
cardiogenic shock is sometimes associated with cardio-
renal syndrome (oliguria, increased urea and creatinine 
levels concomitant with myocardial failure), which leads 
to longer hospital stays, the need for circulatory support, 
and an increased death rate [15].
First‑line treatment [12, 13, 16–18]
The aim of initial patient management is to restore ade-
quate oxygen delivery to peripheral tissues. This relies 
on emergency support (early recognition, monitoring, 
access), optimizing ventilation/gas exchange (oxygen ther-
apy ± noninvasive or invasive ventilation with a saturation 
objective of >95 % except in cyanotic heart disease patients), 
optimizing the preload and afterload (volume expansion or 
diuretics and fluid restriction, inotropes, discontinuation of 
deleterious medication), and treating curable causes (fluid 
and electrolyte balance, rhythm, or thromboembolic disor-
ders; pneumothorax, tamponade, infection).
Field of application 2: patient pathway, 
management principles, and therapeutic goals
Patient pathway
  • All patients with cardiogenic shock should be trans-
ferred to PICU (strong agreement).
  • Children with cardiogenic shock should be man-
aged by a chain of specialized medical teams which 
adapt their care to the real or potential gravity of the 
patient throughout his/her stay in care. This medical 
chain should be clearly identified by all healthcare 
actors (SAMU, SMUR, pediatric emergency depart-
ments, pediatric cardiology and cardiac surgery 
departments, and PICU) (strong agreement).
  • A telephone hotline to an “expert center” provid-
ing specialized responses should be available 24/24 
(strong agreement).
  • It is strongly advised that regional health agencies offi-
cially designate “expert centers” (strong agreement).
  • The following multidisciplinary expertise should be 
available in such expert centers: pediatric medical 
and interventional cardiology, pediatric anesthesia, 
pediatric thoracic, vascular and cardiac surgery, pedi-
atric intensive care, radiology (notably for interven-
tional vascular procedures), mobile circulatory sup-
port unit (strong agreement).
Does prehospital care such as European pediatric life 
support improve the prognosis of cardiogenic shock?
  • Basic or advanced European pediatric life support 
resuscitation, either prior to arrival or at the hospital 
should be used to reduce morbidity and mortality of 
cardiogenic shock (strong agreement).
  • It is probably not advisable to use high doses of 
adrenaline (≥30  µg/kg) during resuscitation com-
pared with usual doses (strong agreement).
  • Early goal-directed therapy should be based on clini-
cal (diuresis, preload, blood pressure) and laboratory 
(blood pH, lactate levels, continuous venous oxy-
gen saturation) variables as well as echocardiogram 
(strong agreement).
  • Once the acute phase of cardiogenic shock has been 
relieved, the patient should be prescribed appropriate 
oral therapy to treat cardiac insufficiency and should 
be closely monitored (strong agreement).
For non-trauma-related cardiogenic shock, “advanced 
pediatric life support” is associated with reduced mor-
tality [OR 0.58 (0.4–0.84)] and functional morbidity [OR 
0.13 (0.04–0.41)] [19]. No benefit has been observed 
when high doses of adrenaline (0.1  mg/kg IV) are 
injected compared with usual doses (0.01 mg/kg IV) dur-
ing prehospital or hospital management of cardiac arrest 
[20, 21]. Implementing therapeutic goals during shock 
management improves patient survival, notably for septic 
shock [22, 23].
Medications
Usefulness of fluid resuscitation in cardiogenic shock
  • Fluid resuscitation should only be indicated in 
patients with cardiogenic shock after clinical assess-
ment (preload insufficiency); it is advised that echo-
cardiographic evaluation be used during such assess-
ment (strong agreement).
  • Fluid resuscitation with colloids and/or crystalloids 
should not be used in patients with cardiogenic 
shock (strong agreement).
In the FEAST study, despite specific comorbid condi-
tions compared to those seen in industrialized countries, 
the increased mortality of children receiving fluid boluses 
was found to be due to cardiac events (cardiogenic shock) 
related to fluid overload [24].
Usefulness of diuretics in the management of cardiogenic 
shock
  • In children with fluid overload and ventricular dys-
function, diuretics (such as furosemide) should be 
used to return to euvolemic state while monitoring 
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clinical criteria and measuring the cardiac output 
(low level of evidence, strong agreement).
  • It is probably not advisable to use venous perfusions 
of nesiritide (recombinant BNP) in children with car-
diogenic shock (strong agreement).
  • It is probably not advisable to use tolvaptan, a selec-
tive antagonist of the arginine vasopressin receptors 
(V2) that is given orally in children with cardiogenic 
shock (strong agreement).
In children with heart failure already treated with one 
or more inotropes and a loop diuretic, continuous per-
fusion of 0.005–0.02  µg/kg/min nesiritide improves the 
fluid balance and reduces pressure in the right atrium 
after 24  h [25]. Other studies have shown that the con-
tinuous perfusion of 0.01–0.03  µg/kg/min nesiritide 
improves echocardiogram variables (heart rate, left 
ventricular ejection fraction) and laboratory values 
(decreased creatinine, BNP and aldosterone levels) after 
72  h [26]. In a retrospective series of 28 children with 
heart failure and hyponatremia, tolvaptan, a selective 
non-peptide antagonist the arginine vasopressin recep-
tors (V2), improved, when used orally at a dose of 0.3 mg/
kg, both diuresis and sodium levels after 72 h [27].
Usefulness of inotropes in the management of cardiogenic 
shock
  • Dobutamine should be used at a dose of 5–20 µg/kg/
min in cases of cardiogenic shock with maintained 
blood pressure so as to restore cardiac output (strong 
agreement).
  • It is probably advisable to use milrinone (continuous 
perfusion of 0.5–0.75  µg/kg/min) as an alternative 
to dobutamine in children with cardiogenic shock, 
especially in post-cardiac surgery patients and in 
cases with impaired right ventricle function and/or 
associated pulmonary arterial hypertension (strong 
agreement).
  • Levosimendan (continuous perfusion of 0.1–0.2  µg/
kg/min) may be used as second-line treatment in 
patients with cardiogenic shock who do not respond 
to the usual therapy (dobutamine or milrinone with 
or without diuretics), especially for postoperative 
management after cardiac surgery (strong agree-
ment).
Dobutamine is still the gold standard inotrope for the 
dynamic assessment of the cardiovascular system and 
is used as the reference inotrope in comparative studies 
[28]. After cardiac surgery, low doses (2.5 µg/kg/min) of 
dobutamine increase the cardiac index and high doses 
(20  µg/kg/min) improve the cardiac index in patients 
with Alagille syndrome [29, 30]. Its hemodynamic effects 
are identical to those of dopamine but without leading to 
increased pulmonary vascular resistance [31]. A review 
has been recently published regarding pharmacokinet-
ics and pharmacodynamics of dobutamine in neonates, 
including studies in children [32].
When used to treat septic shock with normo/hypokine-
sia and compared with a placebo, milrinone (loading dose 
of 50 µg/kg, followed by continuous perfusion of 0.5 µg/
kg/min for 2 h) increases the cardiac index, stroke volume 
index, and oxygen delivery (DO2) and reduces systemic 
and pulmonary vascular resistance and the mean pulmo-
nary arterial pressure 30  min, 1  h, and 2  h after a load-
ing dose of 50 µg/kg [33]. Bailey et al. [34] demonstrated 
that the standardized loading dose of 50 µg/kg over 5 min 
was associated with a 12 % decrease of the mean arterial 
pressure and an 18 % increase of the cardiac index. Some 
authors have compared a placebo group with both a “low 
dose” group (25 µg/kg over 60 min, followed by continu-
ous perfusion of 0.25  µg/kg/min for 35  h) and a “high 
dose” group (75 µg/kg over 60 min, followed by continu-
ous perfusion of 0.75 µg/kg/min for 35 h). The high dose 
of milrinone reduced the risk of low cardiac output by 
55 % at 36 h (p = 0.023) and by 48 % at 30 days (p = 0.049) 
[35]. In practice, the loading dose of milrinone has been 
abandoned due to the risk of vasoplegia. In a series of 40 
post-cardiac surgery children, Lechner et  al. [36] found 
that levosimendan (0.1  µg/kg/min) had a greater effect 
than milrinone (0.5 µg/kg/min) on cardiac index and car-
diac output. In 15 children with acute heart failure, levosi-
mendan was associated with an improved left ventricular 
end systolic fraction and allowed the patients to be given 
lower doses of catecholamines [37]. As for milrinone, in 
practice, the loading dose of levosimendan has been aban-
doned due to the risk of vasoplegia.
Usefulness of vasopressors in the management 
of cardiogenic shock
  • If vasopressors are combined with inotropes to 
achieve adequate perfusion pressure, it is prob-
ably advisable to use noradrenaline as first-line treat-
ment, especially in patients with low cardiac output, 
reduced vascular resistance, and persistent hypoten-
sion (strong agreement).
  • Noradrenaline should be replaced by adrenaline in 
patients with inotrope-resistant cardiogenic shock 
(strong agreement).
  • It is probably not advisable to use dopamine to treat 
cardiogenic shock in children (strong agreement).
  • It is probably advisable to use terlipressin/arginine 
vasopressin as last-resort treatment in children with 
vasopressor-resistant cardiogenic shock (common 
vasopressors such as noradrenaline and adrenaline) 
(strong agreement).
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In 2011, Levy et al. [38] demonstrated the advantage 
of combining the use of norepinephrine, dobutamine, 
and dopamine in adult patients with cardiogenic shock. 
Two forms of the arginine vasopressin (AVP) hormone 
are used in clinical practice: exogenous AVP and terli-
pressin, a synthetic analog with a longer half-life (6  h 
vs. 24  min for AVP). There are thirty-five reports in 
the literature on its clinical use in neonates, children, 
and adolescents; seven of the studies investigated its 
use in patients with low cardiac output and/or severe 
vasodilation after cardiac surgery, and four for cardio-
pulmonary resuscitation [39]. In the context of pedi-
atric cardiac surgery (neonates and children), it seems 
more likely that the positive effects of exogenous AVP 
[40] and terlipressin [41] are due to restored vascular 
tone than to improved left ventricular function [42, 43]. 
However, analysis of the pediatric cases recorded in the 
North American registry of cardiopulmonary resus-
citated patients suggested that AVP had a deleterious 
effect on the possibility of return of spontaneous circu-
lation [44].
Usefulness of vasodilators in the management of cardiogenic 
shock
  • It is probably not advisable to use nitrated derivatives 
to treat cardiogenic shock in children (strong agree-
ment).
Several series of cases evidenced a positive effect when 
nitroprussiate was used to treat patients with low cardiac 
output after cardiac surgery [45, 46]. Similar findings 
were reported for acute cardiac failure [47].
Usefulness of antiarrhythmic agents in the management 
of cardiogenic shock
  • Beta-blockers should not be used to treat cardiogenic 
shock in children (strong agreement).
Meta-analysis of three studies assessing the effect of 
beta-blockers in children with chronic congestive heart 
failure produced conflicting results. The study with the 
largest population (161 children) demonstrated the non-
superiority of carvedilol over placebo using a composite 
score for heart failure [48]. Another study suggested the 
superiority of procainamide over amiodarone for emer-
gency treatment of recurring supraventricular tachycar-
dia [49].
Other therapeutic principles
Usefulness of sedation/analgesia in cardiogenic shock
  • No expert recommendations
Usefulness of anticoagulants/anti‑aggregation agents 
in cardiogenic shock
  • No expert recommendations
Usefulness of therapeutic hypothermia in cardiogenic shock
  • No expert recommendations
Usefulness of continuous renal replacement therapy 
in cardiogenic shock
  • No expert recommendations
Usefulness of transfusion in cardiogenic shock
  • No expert recommendations
Usefulness of immunoglobulins in the management 
of cardiogenic shock in children with myocarditis
  • In cases of acute myocarditis with cardiogenic shock, 
it is probably not advisable to use immunoglobulins 
(strong agreement).
According to a recent report, fulminant myocarditis 
results in cardiogenic shock in 28 % of cases [9]. No pro-
spective randomized pediatric studies have assessed the 
use of immunoglobulins to treat acute myocarditis [50]. 
The largest multicenter trial, a retrospective study on 100 
patients, showed that treatment with immunoglobulins 
did not improve pediatric patient survival, whatever the 
severity score [51].
Usefulness of immunosuppressive therapy in the 
management of cardiogenic shock in children 
with myocarditis
  • In cases of acute myocarditis with cardiogenic shock, 
it is probably not advisable to use immunosuppres-
sant drugs (strong agreement).
Meta-analysis of 9 studies (a total of 139 children 
treated with different immunosuppressant drugs) showed 
no benefit of immunosuppressive therapy in patients 
with myocarditis [52]. Two randomized prospective stud-
ies showed a favorable effect on restoring left ventricular 
function in children with chronic heart failure following 
myocarditis [53, 54], but combined the use of variable 
doses of corticoids, azathioprine, and ciclosporine.
Comparison of the usefulness of noninvasive ventilation 
versus invasive ventilation in the management of cardiogenic 
shock
  • Noninvasive ventilation should not be preferred over 
invasive ventilation in children with cardiogenic 
shock (strong agreement).
No studies have compared the use of noninvasive ven-
tilation and invasive ventilation in children with acute 
heart failure. Noninvasive ventilation (continuous positive 
airway pressure or Bi-level airway pressure) is effective in 
66–80 % of cases when used in pediatric post-cardiac sur-
gery patients, notably in the presence of atelectasis or pul-
monary edema [55, 56]. A team from Turkey reported the 
use of a noninvasive ventilation with a helmet in 3 children 
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aged 18 months, 5 years, and 7 years with cardiogenic pul-
monary edema following scorpion envenomation [57].
Usefulness of cardiac resynchronization therapy in the 
management of cardiogenic shock
  • Cardiac resynchronization therapy should not be 
used in children with cardiogenic shock (low overall 
level of evidence, strong agreement).
No studies have investigated the usefulness of cardiac 
resynchronization therapy in pediatric patients with 
cardiogenic shock. Nevertheless, few studies have been 
carried out on children with severe acute heart failure 
following cardiac surgery. These studies are based on 
small numbers of hemodynamically stable patients and 
did not include control groups [58–62].
Field of application 3: monitoring hemodynamic 
and biological variables
Usefulness of clinical monitoring in the management 
of cardiogenic shock
  • Patients with cardiogenic shock should be clinically 
examined several times a day to evaluate the effec-
tiveness or in-effectiveness of treatment (pulse vol-
ume, peripheral perfusion, heart rate, preload, hepa-
tomegaly, auscultation crackles, distended jugular 
veins, edema syndrome) (strong agreement).
  • Monitoring data for children with cardiogenic shock 
should also include hourly diuresis measurements 
and the input/output balance (strong agreement).
On auscultation of children with cardiogenic shock, 
tachycardia, gallop rhythm, heart murmur, and signs of 
lung congestion can be detected. Peripheral pulses are 
often weakest. Hepatomegaly, distended jugular veins, 
and peripheral edema are nearly always detected in chil-
dren with cardiogenic shock [63]. In infants, supraven-
tricular tachycardia should be suspected if tachycardia 
with a heart rate >220 bpm occurs suddenly.
Usefulness of chest X‑rays in the management 
of cardiogenic shock
  • The initial examination of cardiogenic shock patients 
should include a chest X-ray (low level of evidence, 
strong agreement).
Chest X-ray generally shows cardiomegaly (antero-pos-
terior projection, end-inspiration; cardiothoracic ratio 
>0.6 in neonates, >0.55 in infants, and >0.5 in children). 
Chest X-ray is used to assess the state of the parenchyma 
and lung vessels. They can evidence perihilar fluffy opaci-
ties with butterfly/bat wing patterns (pulmonary edema 
of cardiogenic origin), the water bottle sign (pericardial 
effusion), or a boot-shaped heart (right ventricular dilata-
tion) [63–66].
Usefulness of monitoring laboratory values in the 
management of cardiogenic shock
  • Arterial pH and blood lactate levels should be deter-
mined repeated to assess the course of shock and 
evaluate the efficacy of therapeutic measures (strong 
agreement).
  • The levels of the following variables should be quan-
tified at regular intervals to assess organ dysfunc-
tion in patients with cardiogenic shock: plasma ions, 
blood urea and creatinine, blood glucose, transami-
nases (strong agreement).
  • Repeated determination of CPK-MB levels
•  It is probably not advisable to determine blood 
CPK-MB levels in patients with cardiogenic 
shock (strong agreement).
  • Repeated determination of NT-proBNP levels
•  BNP/NT-proBNP levels should be quantified 
at regular intervals in patients with cardiogenic 
shock to assess the severity of heart disease 
(strong agreement).
  • Repeated determination of troponin levels
•  Troponin levels should be quantified at regular 
intervals in patients with cardiogenic shock to 
assess the severity of myocardial involvement as 
well as the response to treatment (strong agree-
ment).
Blood lactate level, used as a predictor of mortality, is 
one of the therapy goals for sepsis management in both 
children and adults [67]; depending on the studies, the 
goal value ranges from 2 to 3 mmol/L [68, 69]. Increased 
lactate levels can be due to the use of inotropes (adrena-
line, dobutamine), hyperventilation, and impaired mito-
chondrial function without circulatory collapse, and 
certain volume expansion fluids [70]. In patients with 
cardiogenic shock, the increase in CPK-MB is not cor-
related with the severity of myocardial involvement [71]. 
The different troponin isoforms are more specific and 
sensitive markers of acute myocardial involvement than 
CPK-MB [71]; even though to date and unlike what is 
observed in adults, the prognostic value of troponin is 
not clearly established in pediatric patients with cardio-
genic shock [72]. In neonates and children, the normal 
values of troponin and CPK-MB are 0.2–0.4 and 0.6 µg/L, 
respectively. The prognostic value of BNP in children 
with cardiogenic shock has not been demonstrated for-
mally even though its determination is still used widely to 
assess the severity of cardiac involvement, particularly in 
patients with preexisting cardiomyopathy [73]. A recent 
report based on 181 pediatric cases demonstrated the 
relevance of BNP when assessing the severity of conges-
tive heart failure [74]. Gessler et  al. [75] demonstrated 
that the increase in preoperative NT-proBNP levels was 
associated with the quantity of inotropes used during 
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the postoperative period in 40 children who underwent 
cardiac surgery. However, these results have yet to be 
confirmed by other teams [76]. At the beginning of the 
twenty-first century, the use of NT-proBNP levels as a 
marker discriminating between the pulmonary and car-
diac causes of dyspnea was assessed in children [77]. In 
adults with cardiogenic shock, BNP levels appear to cor-
relate well with mortality and morbidity rates [78].
Usefulness of hemodynamic monitoring 
in cardiogenic shock
Usefulness of noninvasive hemodynamic monitoring 
in cardiogenic shock
Oxygen saturation: SpO2
  • SpO2 values should be monitored continuously in 
children with cardiogenic shock (strong agreement).
  • SpO2 is an essential indicator for monitoring a 
patient with decompensated circulatory failure. Its 
value should be evaluated together with clinical 
assessment and arterial blood gas values (SaO2) [11, 
79].
Electrocardiogram: ECG
  • Patients with cardiogenic shock should undergo ECG 
examination in order to guide diagnosis (pericarditis, 
myocarditis, coronary ischemia, pulmonary embo-
lization) and/or diagnose possible rhythm disorders 
that are causing cardiogenic shock (strong agree-
ment).
  • If in doubt, a pediatric cardiology team should be 
contacted to analyze the ECG (strong agreement).
  • An ECG is essential and should be repeated at regu-
lar intervals during the course of cardiogenic shock 
in children [63]. It may show abnormalities related to 
underlying heart disease [12], rhythm disorders due 
to cardiomyopathy [80, 81], supraventricular tachy-
cardia or specific signs of an acute condition such as 
pericarditis (microvoltage), viral myocarditis (repo-
larization issues, ST-segment elevation or depression, 
related ventricular rhythm disorders), myocardial 
infarction in Kawasaki disease (Q wave, ST-segment 
depression), or drug intoxication [65].
Noninvasive arterial pressure
  • We strongly recommend use of an arterial catheter to 
measure the arterial blood pressure in patients with 
decompensated circulatory failure as seen in cardio-
genic shock (strong agreement).
  • Only invasive techniques provide reliable measure-
ments in such patients with circulatory failure, espe-
cially when decompensated [82]. Noninvasive arterial 
blood pressure measurements can be complicated 
to obtain in neonates [83] and require special equip-
ment. The authors of one study [84] advise using an 
arm cuff of width equal to 40  % of the upper arm 
circumference. However, this technique overesti-
mates the diastolic blood pressure. If blood pressure 
is difficult to measure noninvasively in a child with 
impaired consciousness and an irregular O2 satura-
tion curve, then hemodynamic failure can be sus-
pected.
Usefulness of TTE monitoring in cardiogenic shock 
  • We strongly recommend that all PICU have a 24/7 
transthoracic echocardiogram (TTE) service (strong 
agreement).
  • In patients with acute circulatory failure as seen in 
cardiogenic shock, TTE should be used to assess car-
diac function (strong agreement).
  • We strongly advise contacting a pediatric cardiol-
ogy team (by phone, bedside visit, etc.) if a child with 
cardiogenic shock is admitted to PICU (strong agree-
ment).
  • In cardiogenic shock patients, at least the following 
items should be assessed using TTE: systolic and 
diastolic function of both ventricles, pulmonary pres-
sures and coronary visualization, confirmation of 
normal cardiac structure (strong agreement).
  • We strongly advise use of TTE when performing per-
icardial puncture in patients with tamponade (ultra-
sound-guided drainage) (strong agreement).
  • TTE should be performed if a patient suffers from 
cardiogenic shock following cardiac surgery (strong 
agreement).
  • We strongly recommend that specific certification 
courses in TTE be implemented at the national level 
for neonatal and pediatric intensive care practition-
ers (strong agreement).
TTE is recommended in the management of septic 
shock [85]. Few studies focus on the diagnostic and prog-
nostic value of TTE in pediatric cases of cardiogenic 
shock [86]. It is the ideal point-of-care technique [87]. 
TTE enables even those with minimal training to rapidly 
detect pericardial effusion or impaired left ventricular 
function [88, 89]. It can also be used to assess the effi-
cacy of therapeutic measures and any related complica-
tions. In scorpion envenomation patients with authentic 
cardiogenic shock, it was shown that early observation 
of proper left ventricular function using TTE had a very 
good positive predictive value for recovery without heart 
failure [86]. TTE should be used at the earliest stage when 
possible in order to detect subclinical abnormalities. 
To monitor the cardiotoxicity of cytotoxic drugs, some 
authors recommend routine TTE assessment before 
administering the drugs and then at 1  week, 6  months, 
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and 1  year [90]. It is essential that residents and senior 
residents receive training on functional TTE in intensive 
care [91].
Usefulness of near‑infrared spectroscopy (NIRS) monitoring 
in cardiogenic shock 
•  Cerebral, mesenteric, or renal NIRS can be used to 
monitor organ perfusion in patients with cardiogenic 
shock (strong agreement).
NIRS measures oxygenation at the microcirculatory 
level in vessels of diameter <1 mm [92]. Its value varies 
from organ to organ and depends on each organ’s metab-
olism. This technique has mostly been used in unstable 
children undergoing cardiac surgery (intra- and postop-
eratively). During extracorporeal circulation, at the time 
of the aortic cross-clamping, cerebral and somatic NIRS 
values can be informative, whereas SpO2 values are not 
available [93]. NIRS values are correlated with continu-
ous venous O2 saturation (ScvO2) in the superior vena 
cava without, however, replacing it [94]. Chakravarti 
et al. [95] showed that in post-cardiac surgery patients a 
cerebral and/or renal NIRS value of <65 % was predictive 
of a lactate level of over 3 mmol/L which in turn reflects 
tissue hypoperfusion related to reduced cardiac output. 
Other authors have shown that in neonates and infants 
with congenital heart disease requiring surgery or cath-
eterization, the splanchnic NIRS value was correlated 
with SvO2, lactate levels, and gastric pH [96]. Recent case 
reports have demonstrated the usefulness of cerebral and 
renal NIRS as a guide for resuscitation of children in car-
diac arrest [97, 98].
Usefulness of invasive hemodynamic monitoring
Usefulness of arterial oxygen pressure (PaO2)/central venous 
pressure (CVP) monitoring in cardiogenic shock
  • It is advised to monitor SaO2 and PaO2 values in 
patients with severe respiratory diseases, some of 
which can be associated with or cause severe heart 
failure (strong agreement).
  • It is advised to monitor PaO2 by measuring arterial 
blood gas in patients with decompensated circulatory 
failure (strong agreement).
  • Vascular access should be obtained in patient with 
cardiogenic shock by inserting a central venous 
catheter, preferably in the superior vena cava (strong 
agreement).
  • CVP values (and moreover CVP kinetics in a given 
patient) can provide information on the preload 
reserve in children with cardiogenic shock (strong 
agreement).
 If possible CVP measurements should be performed 
at the end of expiration, and without mechanical ventila-
tion running (apnea). According to some authors, if the 
same values are obtained with and without mechanical 
ventilation, subsequent measurements can be performed 
with ventilation [70, 99]. Usual CVP values range from 2 
to 8 cm H2O (1–6 mm Hg). Return to normal CVP values 
is one of the goals of sepsis management in children [67]. 
The CVP value provides information on right ventricular 
preload; however, the relevance of this measurement in 
unstable, intubated, and ventilated children is limited.
Usefulness of central venous oxygen saturation (ScvO2) 
monitoring in cardiogenic shock
  • We strongly recommend that ScvO2 be measured 
continuously or discontinuously in the superior vena 
cava during cardiogenic shock (strong agreement).
  • We strongly recommend aiming to reach an upper 
target value of 70  % (which reflects normal arterial 
oxygen transport). A value <65–70  % with persis-
tent clinical and laboratory signs of shock can reflect 
inadequate arterial oxygen transport and should 
spur efforts to improve oxygen transport by increas-
ing cardiac output and/or transfusion of packed red 
blood cells (strong agreement).
  • It is advised to monitor SaO2 and PaO2 values in 
patients with severe respiratory diseases, some of 
which can be associated with or can cause severe 
heart failure (strong agreement).
Continuous central venous oxygen saturation (ScvO2), 
a variable used to assess microcirculatory and macro-
circulatory hemodynamics, provides information on the 
balance between demand and supply of O2 to the tis-
sues. It is measured in the superior vena cava [100] and 
is one of the goals set by the Surviving Sepsis Campaign 
(>70 %) [67]. The reliability of SvcO2 measurements com-
pared with SVO2 values obtained using pulmonary artery 
catheters is a subject of discussion. Grissom et al. [101] 
showed that if the ScvO2 value measured in the superior 
vena cava ≥70  % in adults with acute lung injury,  then 
it was unlikely that the mixed venous oxygen saturation 
(SvO2) value measured by pulmonary artery catheter 
would be <60 %. On the other hand, a ScvO2 value <70 % 
did not reliably predict a SVO2 value <60 % (positive pre-
dictive value of 31 %). ScvO2 measurements overestimate 
the SVO2 by approximately 3–8 %. The kinetics of these 
2 variables are fairly well, although not perfectly, corre-
lated [102]. Recently, De Oliveira et al. [22] demonstrated 
that a significant decrease in mortality could be achieved 
if a target value of ScvO2 >70  % was implemented in 
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sepsis management in children. ScvO2 can be considered 
as an interesting marker while not perfect of the balance 
between oxygen transport and tissue oxygen consump-
tion. In case of shock, and particularly in case of septic 
shock, changes and heterogeneity of regional and tissue 
flows should give cautious to an analysis of ScvO2 value 
alone.
Usefulness of invasive arterial pressure monitoring 
in cardiogenic shock
  • We strongly advise use of an arterial catheter to 
measure arterial blood pressure in patients with 
decompensated circulatory failure as seen in cardio-
genic shock (strong agreement).
Radial access (palmar arch) should be preferred in 
children even if the validity of the Allen test is not une-
quivocal. Arterial catheters allow unstable children to be 
monitored, especially if receiving inotropes or vasopres-
sors [70]. Intraoperative and postoperative monitoring 
during cardiac surgery or other prolonged or potentially 
hemorrhagic surgical procedures requires hemodynamic 
measurements with invasive arterial pressure readings.
Usefulness of pulmonary arterial pressure/SvO2 monitoring 
in cardiogenic shock
  • In patients with cardiogenic shock who do not 
respond to first-line treatment, pulmonary artery 
catheter placement, if necessary, should be per-
formed by a team familiar with this technique (strong 
agreement).
  • Routine pulmonary artery catheter placement is not 
recommended in children with cardiogenic shock 
(strong agreement).
Pulmonary artery catheter is only rarely used in chil-
dren even if their placement in adults is the standard 
technique for measuring cardiac output [103]. Pul-
monary artery catheter measures the heart chamber 
pressures and cardiac output using thermodilution. 
Pulmonary artery catheter also provides continuous 
information about the mixed venous oxygen saturation 
(SvO2) and right ventricular ejection fraction and ena-
bles placement of an electrosystolic probe in the right 
ventricle. Finally, pulmonary artery catheter can be 
used to perfuse the patient and collect blood samples 
from each heart chamber. Additional file  1: Table  S1 
summarizes the normal values of variables measured 
or calculated using a pulmonary artery catheter [104]. 
The variation in the values measured using the pul-
monary artery catheter provides information on the 
patient’s hemodynamic and circulatory status. Right 
atrium pressure increases with hypervolemia, right 
ventricular dysfunction, or increased juxtacardiac 
pressure (pericarditis, pneumothorax, and elevated 
positive expiratory pressure). Pulmonary artery pres-
sure increases with pulmonary arterial hypertension, 
left ventricular dysfunction, pulmonary embolization, 
intracardiac shunts (heart disease or lung disease), and 
positive expiratory pressure and, in contrast, decreases 
with hypovolemia, shock, right ventricular impairment, 
and lung failure. Pulmonary arterial wedge pressure 
increases with hypervolemia, left ventricular impair-
ment, increased left ventricular afterload, and increased 
juxtacardiac pressure and decreases with hypovolemic, 
distributive, and septic shock.
Usefulness of thermodilution cardiac output monitoring 
in cardiogenic shock
  • Cardiac output determination by thermodilution/
pulse contour analysis using a PICCO®-type system 
may be considered in patients with cardiogenic shock 
refractory to first-line treatment (strong agreement).
Cardiac output determination by thermodilution 
has been developed in adults using a pulmonary artery 
catheter (Pulmonary Arterial ThermoDilution). Less 
invasive methods have also been developed to deter-
mine the cardiac output by thermodilution using 
a central venous catheter and an arterial catheter 
(TransPulmonary ThermoDilution, TPTD). Such meth-
ods have been validated in animals [105] and children 
[106, 107], in particular by comparison with Pulmo-
nary Arterial ThermoDilution values or using the Fick 
equation. Two methods exist: the PICCO™ system 
(Pulsion Medical Systems, Munich, Germany) which 
uses thermodilution  +  waveform and the LiDCO™ 
system (LiDCO Ltd, Cambridge, UK) which uses dilu-
tion +  PulseCO. The PICCO™ system uses a solution 
of cold saline or dextrose (thermodilution) at 13 °C less 
than the body temperature (in practice often close to 
0 °C) that is injected via the central catheter (subclavian 
or internal jugular) and detected by a thermistor placed 
in an arterial catheter in the femoral area. This method 
is easy to set up but requires frequent calibration. The 
LiDCO™ system uses a solution of lithium chloride 
(lithium dilution) which has the advantage that it can 
be injected via a peripheral venous catheter. The solu-
tion is then detected by a sensor on a catheter placed in 
the radial artery [108]. Cardiac output determinations 
using the LiDCO™ system are very well correlated with 
Pulmonary Arterial ThermoDilution measurements 
[108] as well as with values obtained using the PICCO™ 
system [103]. However, the use of LIDCO has a very 
limited experience in childhood and has not been vali-
dated yet in such circumstances.
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Field of application 4: circulatory support 
(indications, techniques, organization, and transfer 
criteria)
First-line circulatory support in children with cardiogenic 
shock is venoarterial extracorporeal membrane oxygena-
tion (ECMO). In 1992, del Nido et  al. [109] suggested 
using ECMO for cardiac arrest (extracorporeal cardio-
pulmonary resuscitation) at an early stage during the 
low cardiac output phase to reduce neurological com-
plications. ECMO maintains tissue oxygenation pend-
ing recovery of heart function. Frequent use of ECMO 
following cardiac surgery for congenital or acquired 
Fig. 2 Decision tree for the management of children with a cardiogenic shock. (PEEP positive end expiratory pressure, SVR systemic vascular resist‑
ance)
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cardiomyopathy in pediatric patients has led care facili-
ties to purchase the specialized equipment needed for 
this technique.
Usefulness of arteriovenous extracorporeal membrane 
oxygenation for the management of cardiogenic shock 
in children
  • We strongly recommend using ECMO in patients 
with cardiogenic shock refractory to conventional 
therapy (strong agreement).
No prospective randomized studies have been carried 
out on pediatric populations to compare morbidity and 
mortality of patients with cardiogenic shock or cardiac 
arrest with or without circulatory support by ECMO. 
Analysis of the Extracorporeal Life Support Organiza-
tion (ELSO) registry (https://www.elso.org/), which in 
July 2013 included information on 55,668 patients, shows 
that the use of ECMO has decreased since 1992 in neo-
nates and pediatric patients for respiratory indications 
(since when inhaled nitric oxide has been used in clinical 
practice), but has increased continuously over the same 
period for cardiac indications. Two main indications are 
observed: severe heart failure or cardiogenic shock and 
cardiac arrest. Delayed use of ECMO in patients with 
cardiogenic shock increases the risk of cardiac arrest. 
Numerous retrospective studies [110–120], as well as 
data from the ELSO registry (https://www.elso.org/), 
show that when ECMO is used the mean patient sur-
vival is >40  % for cardiogenic shock and >35  % for car-
diac arrest. The prognosis for myocarditis is very good if 
ECMO is started prior to cardiac arrest [121–124]. The 
complications associated with ECMO are mostly neuro-
logical: electrical and clinical seizure, cerebral infarction 
and bleeding, brain death. Depending on patient popu-
lations, Brown et  al. [121] reported persisting low-to-
moderate disabilities in 12–50 % of patients treated with 
ECMO. In 16 survivors of a series of 39 children treated 
with ECMO, Lequier et al. [125] reported a mean score 
of 73  ±  16 on the Bayley scale at 2  years of age. Eight 
patients showed moderate mental retardation.
Extracorporeal membrane oxygenation in patients 
with cardiac arrest
  • We strongly recommend using ECMO in patients 
with cardiac arrest within ≥15  min and <60  min 
(strong agreement).
According to International Liaison Committee on 
Resuscitation, use of ECMO should be considered 
in children with cardiac arrest refractory to conven-
tional cardiopulmonary resuscitation, if cardiac arrest 
occurred in a highly monitored setting and the neces-
sary support equipment and expertise are available to 
implement the technique rapidly [126]. In a series of 682 
patients with a median age of 3 months (ELSO registry) 
treated with extracorporeal cardiopulmonary resusci-
tation [127], the survival rate after discharge was 38 %. 
This study suggests that a pH  <  6.9 prior to ECMO is 
significantly associated with death within 72 h or a poor 
neurological prognosis. The meta-analysis performed 
by Tajik and Cardarelli [128] of 37 studies (288 patients) 
including case reports and observational pediatric stud-
ies on patients with cardiac arrest treated with extra-
corporeal cardiopulmonary resuscitation, showed that 
survival rate was very variable: It ranged from 0 to 100 % 
in small centers that had low numbers of patients and 
from 6 to 79 % for the larger cohorts. Matos et al. [116] 
demonstrated that morbidity and mortality increase if 
cardiopulmonary resuscitation lasts >15  min and that 
conventional resuscitation reaches its limits with a likeli-
hood of survival of 41 % for cardiopulmonary resuscita-
tion lasting 1–15 min, but only 12 % if cardiopulmonary 
resuscitation lasts >35  min. The neurological prognosis 
of survivors is good and reaches 70  % when cardiopul-
monary resuscitation lasts <15  min and 60  % if CPR 
lasts <35 min. The survival of children undergoing car-
diac surgery is 38.5  % if cardiopulmonary resuscitation 
lasts >35  min and ECMO is used, but drops to 16.7  % 
if ECMO is not used (p  <  0.0001). Turek et  al. [120] 
reported that if ECMO was implemented within 40 min 
using a previously prepared circuit, neurological com-
plications were decreased by 52 % (p < 0.04) compared 
with the conventional method (>40  min). However, no 
decrease in the mortality rate was observed. In a series 
of 42 children treated with extracorporeal cardiopulmo-
nary resuscitation, Delmo-Walter et  al. [112] showed a 
difference of mortality depending on the duration of 
cardiopulmonary resuscitation prior to implementation 
of ECMO: 30 ±  1.3  min vs. 46 ±  4.2  min (p =  0.003). 
The faster the limits of cardiopulmonary resuscitation 
are recognized, the earlier ECMO should be initiated, 
thereby limiting mortality and organ lesions [129].
Usefulness of mechanical ventricular assist devices in the 
management of cardiogenic shock in children
  • We recommend that the use of ventricular assist 
devices in pediatric patients with cardiogenic shock 
refractory to conventional therapy be discussed with 
cardiologists (strong agreement).
No prospective randomized studies have been per-
formed to compare the morbidity and mortality of chil-
dren with cardiogenic shock treated with or without a 
ventricular assist device. In a single-center retrospective 
study including 16 children with fulminant myocarditis, 
Wilmot et al. [124] reported a survival rate of 75 % at dis-
charge whatever the support method used (ventricular 
assist device or ECMO).
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Usefulness of extracorporeal membrane oxygenation 
implementation criteria for children with cardiogenic 
shock
  • To lower the risks of mortality and neurological mor-
bidity, we strongly recommend implementing ECMO 
when pH  ≥  7.2 and lactate  <  9  mmol/L and using 
low-to-moderate inotrope support (strong agree-
ment).
  • The decision to implement ECMO in children with 
cardiogenic shock is based on clinical, laboratory, 
and prognostic criteria, the relevance of which must 
be considered jointly by pediatric cardiologists and 
intensive care physicians (strong agreement).
No prospective randomized studies have been per-
formed to define specific criteria for ECMO implemen-
tation in children with cardiogenic shock. Based on data 
from the ELSO registry in 2005, Thiagarajan et al. [127] 
reported a mean pre-ECMO arterial pH of 7.26 (7.06–
7.38) for survivors and 7.17 (6.9–7.36) for non-survivors 
(p = 0.001). Multivariate analysis demonstrated that the 
mean pre-ECMO pH was <6.9 in the group of children 
with the highest mortality. For the same patient popula-
tion, Barrett et  al. [130] demonstrated that neurological 
prognosis was poorest for children with a pH  <  6.865. 
Two studies by Huang et  al. [114, 131], which included 
27 and 54 cases of extracorporeal cardiopulmonary 
resuscitation and 41 and 46 % of survivors, respectively, 
revealed that pre-ECMO lactate levels were statistically 
higher in non-survivors than in survivors [for the first 
study 14 (10.2–19.6) vs. 8.5 (4.4–12.6) mmol/L, p < 0.01 
and for the second study 13.4 ± 6.4 vs. 8.8 ± 5.1 mmol/L, 
p < 0.01]. In 218 post-cardiac surgery pediatric patients, 
Trittenwein et al. [132] reported that the predicted post-
operative mortality was 80 % if the patient showed arte-
rial lactate levels >7.7  mmol/L with ScvO2 <60  %, or if 
arterial lactate levels >18  mmol/L and ScvO2  >60  % on 
admission to intensive care (p < 0.05). The authors sug-
gest that these levels be used as postoperative criteria for 
ECMO implementation.
Usefulness of mobile circulatory support units 
for implementing extracorporeal membrane oxygenation 
in patients with cardiogenic shock far from an expert 
center
  • ECMO should be implemented by a team of trained 
healthcare professionals (strong agreement).
  • Patients treated with ECMO should be transferred to 
an expert center (strong agreement).
No randomized studies have been performed on the 
use of mobile circulatory support units. Before request-
ing a mobile circulatory support unit, the child’s status 
(cardiogenic shock/cardiac arrest), on-site therapeutic 
means and hemodynamic assessment measures, and the 
response time of the mobile circulatory support unit 
should be taken into account.
Usefulness of expert centers for managing pediatric 
patients with cardiogenic shock treated with venoarterial 
extracorporeal membrane oxygenation
  • Candidate pediatric ECMO reference centers should 
perform at least 15–20 ECMOs on pediatric patients 
per year (strong agreement).
No randomized studies have been performed on expert 
pediatric ECMO centers.
An expert center must have a multidisciplinary tech-
nical platform that can ensure complete care of pediat-
ric patients treated with ECMO for both medical and 
surgical indications. In a study based on 3867 pediatric 
congenital cardiopathy patients treated with ECMO, Kar-
amlou et al. [133] showed that low in-hospital mortality 
was associated with centers that managed large numbers 
of ECMO cases (>30/year; p = 0.01), whereas low ECMO 
activity (<15/year) was a risk factor for in-hospital mor-
tality (OR 1.75; CI 95 % 1.03–2.94; p = 0.03).
Conclusion
We report here experts’ recommendations regard-
ing management of children with cardiogenic shock. 
We hope this work will help healthcare professionals in 
their daily practice. We propose in conclusion a decision 
tree (Fig.  2) for the management of cardiogenic shock 
in children by referring to recommendations we have 
published.
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Expert recommendations: introduction and description of the meth-
odology: The present recommendations, which build on the risk manage‑
ment compendium in cardiology and contribute to the quality improvement 
program implemented by our approved bodies, are the product of work 
carried out by a group of experts convened by the Société de Réanimation 
de Langue Française (SRLF; French Intensive Care Society) and the Groupe 
Francophone de Réanimation et Urgences Pédiatriques (GFRUP; French Group 
for Pediatric Intensive Care and Emergencies). Four pediatric experts provided 
clinical justifications for each of the four fields of application defined by the 
organization committee. Because the fields of application differ greatly in 
adults, we chose to formulate recommendations for pediatric patients. For the 
most part, our recommendations arise from prospective and retrospective 
observational studies and international consensus. All proposed recommen‑
dations were reviewed and discussed individually, each expert being asked to 
justify the substance and format of his/her proposals, and potentially amend 
them to take into account comments from peers. Proposals were then rated 
by the four designated experts and seven associate pediatric experts, all 
qualified in the specific field. The aim of this review process was not necessar‑
ily to reach a single, convergent opinion for each proposal, but to delineate 
clearly areas of agreement on which the recommendations are based as well 
as points of contention or indecision that require further investigation. Each 
expert rated each recommendation using the RAND/UCLA appropriateness 
method with three rating rounds after eliminating outliers (experts with devi‑
ating opinions). Each proposal was rated using a numerical scale ranging from 
1 to 9 (1 being “disagree entirely,” “total lack of evidence,” or “strictly contraindi‑
cated” and 9 being “agree entirely,” “formal evidence,” or “formally indicated”). 
Three rating zones were then defined depending on the value of the median: 
the “disagreement” zone (1–3); the “indecision” zone (4–6); and the “agreement” 
zone (7–9). The agreement, disagreement, or indecision was said to be “strong” 
if the median interval was included within one of the three zones (1–3), (4–6), 
or (7–9). The agreement, disagreement, or indecision was said to be “weak” if 
the median interval impinged on the boundary of another zone (e.g., [1–4] 
or [6–8]). The methodology used to formulate these recommendations was 
based on the GRADE system (http://www.gradeworkinggroup.org//links.htm). 
The originality of the GRADE approach is notably due to the following aspects: 
A level of evidence is not assigned to a study solely on the basis of study type 
(e.g., randomized trial or not); the risk–benefit ratio is taken into account fully; 
finally, when formulating recommendations, the phrases “should be/should 
not be (it is/is not advisable to)” and “it is probably advisable to/not to” have 
clearly distinct meanings for users.
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2015   Accepted: 26 January 2016
References
 1. Levy B, Bastien O, Benjelid K, Cariou A, Chouihed T, Combes A, et al. 
Experts’ recommendations for the management of adult patients with 
cardiogenic shock. Ann Intensive Care. 2015;5(1):52.
 2. Levy B, Bastien O, Karim B, Cariou A, Chouihed T, Combes A, et al. 
Erratum to: experts’ recommendations for the management of adult 
patients with cardiogenic shock. Ann Intensive Care. 2015;5(1):26.
 3. Fisher JD, Nelson DG, Beyersdorf H, Satkowiak LJ. Clinical spectrum of 
shock in the pediatric emergency department. Pediatr Emerg Care. 
2010;26(9):622–5.
 4. Singh D, Chopra A, Pooni PA, Bhatia RC. A clinical profile of shock in 
children in Punjab, India. Indian Pediatr. 2006;43(7):619–23.
 5. Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE, et al. Preva‑
lence, morbidity, and mortality of heart failure‑related hospitalizations 
in children in the United States: a population‑based study. J Card Fail. 
2012;18(6):459–70.
 6. Webster G, Zhang J, Rosenthal D. Comparison of the epidemiology and 
co‑morbidities of heart failure in the pediatric and adult populations: a 
retrospective, cross‑sectional study. BMC Cardiovasc Disord. 2006;6:23.
 7. Andrews RE, Fenton MJ, Ridout DA, Burch M. New‑onset heart failure 
due to heart muscle disease in childhood: a prospective study in the 
United kingdom and Ireland. Circulation. 2008;117(1):79–84.
 8. Massin MM, Astadicko I, Dessy H. Epidemiology of heart failure in a 
tertiary pediatric center. Clin Cardiol. 2008;31(8):388–91.
 9. Saji T, Matsuura H, Hasegawa K, Nishikawa T, Yamamoto E, Ohki H, et al. 
Comparison of the clinical presentation, treatment, and outcome of 
fulminant and acute myocarditis in children. Circ J. 2012;76(5):1222–8.
 10. Sommers C, Nagel BH, Neudorf U, Schmaltz AA. Congestive heart failure 
in childhood. An epidemiologic study. Herz. 2005;30(7):652–62.
 11. Biarent D, Bingham R, Eich C, Lopez‑Herce J, Maconochie I, Rodriguez‑
Nunez A, et al. European resuscitation council guidelines for resuscitation 
2010 section 6. Paediatric life support. Resuscitation. 2010;81(10):1364–88.
 12. Chaturvedi V, Saxena A. Heart failure in children: clinical aspect and 
management. Indian J Pediatr. 2009;76(2):195–205.
 13. Kantor PF, Lougheed J, Dancea A, McGillion M, Barbosa N, Chan C, et al. 
Presentation, diagnosis, and medical management of heart failure in 
children: canadian cardiovascular society guidelines. Can J Cardiol. 
2013;29(12):1535–52.
 14. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, et al. 
The pediatric cardiomyopathy registry and heart failure: key results 
from the first 15 years. Heart Fail Clin. 2010;6(4):401–13, vii.
 15. Price JF, Mott AR, Dickerson HA, Jefferies JL, Nelson DP, Chang AC, et al. 
Worsening renal function in children hospitalized with decompensated 
heart failure: evidence for a pediatric cardiorenal syndrome? Pediatr Crit 
Care Med. 2008;9(3):279–84.
 16. James N, Smith M. Treatment of heart failure in children. Curr Paediatr. 
2005;15(7):539–48.
 17. Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, et al. 
International Society for Heart and Lung Transplantation: practice 
guidelines for management of heart failure in children. J Heart Lung 
Transplant. 2004;23(12):1313–33.
 18. Sandroni C, Nolan J. ERC 2010 guidelines for adult and pediatric 
resuscitation: summary of major changes. Minerva Anestesiol. 
2011;77(2):220–6.
 19. Carcillo JA, Kuch BA, Han YY, Day S, Greenwald BM, McCloskey KA, et al. 
Mortality and functional morbidity after use of PALS/APLS by commu‑
nity physicians. Pediatrics. 2009;124(2):500–8.
 20. Patterson MD, Boenning DA, Klein BL, Fuchs S, Smith KM, Hegenbarth 
MA, et al. The use of high‑dose epinephrine for patients with out‑of‑
hospital cardiopulmonary arrest refractory to prehospital interventions. 
Pediatr Emerg Care. 2005;21(4):227–37.
Page 14 of 16Brissaud et al. Ann. Intensive Care  (2016) 6:14 
 21. Perondi MB, Reis AG, Paiva EF, Nadkarni VM, Berg RA. A comparison of 
high‑dose and standard‑dose epinephrine in children with cardiac 
arrest. N Engl J Med. 2004;350(17):1722–30.
 22. de Oliveira CF, de Oliveira DS, Gottschald AF, Moura JD, Costa GA, 
Ventura AC, et al. ACCM/PALS haemodynamic support guidelines for 
paediatric septic shock: an outcomes comparison with and without 
monitoring central venous oxygen saturation. Intensive Care Med. 
2008;34(6):1065–75.
 23. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. 
Early goal‑directed therapy in the treatment of severe sepsis and septic 
shock. N Engl J Med. 2001;345(19):1368–77.
 24. Myburgh J, Finfer S. Causes of death after fluid bolus resuscitation: new 
insights from FEAST. BMC Med. 2013;11:67.
 25. Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide 
in infants and children with congestive heart failure. Pediatr Crit Care 
Med. 2005;6(5):543–6.
 26. Jefferies JL, Price JF, Denfield SW, Chang AC, Dreyer WJ, McMahon CJ, 
et al. Safety and efficacy of nesiritide in pediatric heart failure. J Card 
Fail. 2007;13(7):541–8.
 27. Regen RB, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes AP, 
et al. Tolvaptan increases serum sodium in pediatric patients with heart 
failure. Pediatr Cardiol. 2013;34(6):1463–8.
 28. Strigl S, Beroukhim R, Valente AM, Annese D, Harrington JS, Geva T, et al. 
Feasibility of dobutamine stress cardiovascular magnetic resonance 
imaging in children. J Magn Reson Imaging. 2009;29(2):313–9.
 29. Kwapisz MM, Neuhauser C, Scholz S, Welters ID, Lohr T, Koch T, et al. 
Hemodynamic effects of dobutamine and dopexamine after car‑
diopulmonary bypass in pediatric cardiac surgery. Paediatr Anaesth. 
2009;19(9):862–71.
 30. Razavi RS, Baker A, Qureshi SA, Rosenthal E, Marsh MJ, Leech SC, et al. 
Hemodynamic response to continuous infusion of dobutamine in 
Alagille’s syndrome. Transplantation. 2001;72(5):823–8.
 31. Booker PD, Evans C, Franks R. Comparison of the haemodynamic effects 
of dopamine and dobutamine in young children undergoing cardiac 
surgery. Br J Anaesth. 1995;74(4):419–23.
 32. Mahoney L, Shah G, Crook D, Rojas‑Anaya H, Rabe H. A literature review 
of the pharmacokinetics and pharmacodynamics of dobutamine in 
neonates. Pediatr Cardiol. 2015;37:14–23.
 33. Barton P, Garcia J, Kouatli A, Kitchen L, Zorka A, Lindsay C, et al. Hemo‑
dynamic effects of i.v. milrinone lactate in pediatric patients with septic 
shock. A prospective, double‑blinded, randomized, placebo‑controlled, 
interventional study. Chest. 1996;109(5):1302–12.
 34. Bailey JM, Miller BE, Lu W, Tosone SR, Kanter KR, Tam VK. The phar‑
macokinetics of milrinone in pediatric patients after cardiac surgery. 
Anesthesiology. 1999;90(4):1012–8.
 35. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, 
et al. Efficacy and safety of milrinone in preventing low cardiac output 
syndrome in infants and children after corrective surgery for congenital 
heart disease. Circulation. 2003;107(7):996–1002.
 36. Lechner E, Hofer A, Leitner‑Peneder G, Freynschlag R, Mair R, Weinzettel 
R, et al. Levosimendan versus milrinone in neonates and infants after 
corrective open‑heart surgery: a pilot study. Pediatr Crit Care Med. 
2012;13(5):542–8.
 37. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early expe‑
rience with Levosimendan in children with ventricular dysfunction. 
Pediatr Crit Care Med. 2006;7(5):445–8.
 38. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepineph‑
rine‑dobutamine to epinephrine for hemodynamics, lactate metabo‑
lism, and organ function variables in cardiogenic shock. A prospective, 
randomized pilot study. Crit Care Med. 2011;39(3):450–5.
 39. Meyer S, McGuire W, Gottschling S, Shamdeen GM, Gortner L. The role 
of vasopressin and terlipressin in catecholamine‑resistant shock and 
cardio‑circulatory arrest in children: review of the literature. Wien Med 
Wochenschr. 2011;161(7–8):192–203.
 40. Mastropietro CW, Davalos MC, Seshadri S, Walters HL 3rd, Delius RE. 
Clinical response to arginine vasopressin therapy after paediatric 
cardiac surgery. Cardiol Young. 2013;23(3):387–93.
 41. Matok I, Rubinshtein M, Levy A, Vardi A, Leibovitch L, Mishali D, et al. 
Terlipressin for children with extremely low cardiac output after open 
heart surgery. Ann Pharmacother. 2009;43(3):423–9.
 42. Jerath N, Frndova H, McCrindle BW, Gurofsky R, Humpl T. Clinical impact 
of vasopressin infusion on hemodynamics, liver and renal function in 
pediatric patients. Intensive Care Med. 2008;34(7):1274–80.
 43. Mastropietro CW, Clark JA, Delius RE, Walters HL 3rd, Sarnaik AP. Argi‑
nine vasopressin to manage hypoxemic infants after stage I palliation 
of single ventricle lesions. Pediatr Crit Care Med. 2008;9(5):506–10.
 44. Duncan JM, Meaney P, Simpson P, Berg RA, Nadkarni V, Schexnayder 
S. Vasopressin for in‑hospital pediatric cardiac arrest: results from the 
American Heart Association National Registry of Cardiopulmonary 
Resuscitation. Pediatr Crit Care Med. 2009;10(2):191–5.
 45. Appelbaum A, Blackstone EH, Kouchoukos NT, Kirklin JW. Afterload 
reduction and cardiac ouptut in infants early after intracardiac surgery. 
Am J Cardiol. 1977;39(3):445–51.
 46. Benzing G 3rd, Helmsworth JA, Schrieber JT, Loggie J, Kaplan S. Nitro‑
prusside after open‑heart surgery. Circulation. 1976;54(3):467–71.
 47. Dillon TR, Janos GG, Meyer RA, Benzing G 3rd, Kaplan S. Vasodilator 
therapy for congestive heart failure. J Pediatr. 1980;96(4):623–9.
 48. Frobel AK, Hulpke‑Wette M, Schmidt KG, Laer S. Beta‑blockers for 
congestive heart failure in children. Cochrane Database Syst Rev. 
2009;(1):CD007037.
 49. Chang PM, Silka MJ, Moromisato DY, Bar‑Cohen Y. Amiodarone versus 
procainamide for the acute treatment of recurrent supraventricu‑
lar tachycardia in pediatric patients. Circ Arrhythm Electrophysiol. 
2010;3(2):134–40.
 50. Robinson J, Hartling L, Vandermeer B, Crumley E, Klassen TP. Intravenous 
immunoglobulin for presumed viral myocarditis in children and adults. 
Cochrane Database Syst Rev. 2005;(1):CD004370.
 51. Kim HJ, Yoo GH, Kil HR. Clinical outcome of acute myocarditis 
in children according to treatment modalities. Korean J Pediatr. 
2010;53(7):745–52.
 52. Hia CP, Yip WC, Tai BC, Quek SC. Immunosuppressive therapy in 
acute myocarditis: an 18 year systematic review. Arch Dis Child. 
2004;89(6):580–4.
 53. Aziz KU, Patel N, Sadullah T, Tasneem H, Thawerani H, Talpur S. Acute 
viral myocarditis: role of immunosuppression: a prospective ran‑
domised study. Cardiol Young. 2010;20(5):509–15.
 54. Camargo PR, Snitcowsky R, da Luz PL, Mazzieri R, Higuchi ML, Rati 
M, et al. Favorable effects of immunosuppressive therapy in children 
with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol. 
1995;16(2):61–8.
 55. Gupta P, Kuperstock JE, Hashmi S, Arnolde V, Gossett JM, Prodhan P, 
et al. Efficacy and predictors of success of noninvasive ventilation 
for prevention of extubation failure in critically ill children with heart 
disease. Pediatr Cardiol. 2013;34(4):964–77.
 56. Odena MP, Marimbaldo IP, Matute SS, Argallo MB, Rico AP. Aplicacion de 
ventilacion no invasiva en pacientes postoperados cardiacos. Estudio 
retrospectivo. An Pediatr (Barc). 2009;71(1):13–9.
 57. Yildizdas D, Yilmaz HL, Erdem S. Treatment of cardiogenic pulmonary 
oedema by helmet‑delivered non‑invasive pressure support ventilation 
in children with scorpion sting envenomation. Ann Acad Med Singa‑
pore. 2008;37(3):230–4.
 58. Bacha EA, Zimmerman FJ, Mor‑Avi V, Weinert L, Starr JP, Sugeng L, et al. 
Ventricular resynchronization by multisite pacing improves myocardial 
performance in the postoperative single‑ventricle patient. Ann Thorac 
Surg. 2004;78(5):1678–83.
 59. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, et al. 
Resynchronization therapy in pediatric and congenital heart disease 
patients: an international multicenter study. J Am Coll Cardiol. 
2005;46(12):2277–83.
 60. Janousek J, Gebauer RA, Abdul‑Khaliq H, Turner M, Kornyei L, Grollmuss 
O, et al. Cardiac resynchronisation therapy in paediatric and congenital 
heart disease: differential effects in various anatomical and functional 
substrates. Heart. 2009;95(14):1165–71.
 61. Janousek J, Vojtovic P, Hucin B, Tlaskal T, Gebauer RA, Gebauer R, et al. 
Resynchronization pacing is a useful adjunct to the management of 
acute heart failure after surgery for congenital heart defects. Am J 
Cardiol. 2001;88(2):145–52.
 62. Zimmerman FJ, Starr JP, Koenig PR, Smith P, Hijazi ZM, Bacha EA. Acute 
hemodynamic benefit of multisite ventricular pacing after congenital 
heart surgery. Ann Thorac Surg. 2003;75(6):1775–80.
Page 15 of 16Brissaud et al. Ann. Intensive Care  (2016) 6:14 
 63. Biarent D, Bourdages M, Berner M, Miro J, van Doesburg NH, Toledano 
B. Choc Cardiogénique. In: Lacroix J, Gauthier M, Hubert P, Leclerc F, 
Gaudreault P, editors. Urgences et soins intensifs pediatriques. Masson: 
Edition du Sainte Justine et Elsevier; 2007. p. 187–210.
 64. Kantor PF, Mertens LL. Clinical practice: heart failure in children. Part II: 
current maintenance therapy and new therapeutic approaches. Eur J 
Pediatr. 2010;169(4):403–10.
 65. Kim JJ, Rossano JW, Nelson DP, Price JF, Dreyer WJ. Heart failure in 
infants and children: etiology, pathophysiology, and diagnosis of heart 
failure. In: Nichols DG, editor. Roger’s textbook of pediatric intensive 
care. Philadelphia: Wolters Kluwer/Lippincott, Williams & Wilkins; 2008. 
p. 1064–74.
 66. Zingarelli B. Shock and reperfusion. In: Nichols DG, editor. Roger’s 
textbook of pediatric intensive care. Philadelphia: Wolters Kluwer/Lip‑
pincott, Williams & Wilkins; 2008. p. 252–61.
 67. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. 
Surviving Sepsis Campaign: international guidelines for manage‑
ment of severe sepsis and septic shock: 2008. Crit Care Med. 
2008;36(1):296–327.
 68. Duke TD, Butt W, South M. Predictors of mortality and multiple organ 
failure in children with sepsis. Intensive Care Med. 1997;23(6):684–92.
 69. Hatherill M, McIntyre AG, Wattie M, Murdoch IA. Early hyperlactataemia 
in critically ill children. Intensive Care Med. 2000;26(3):314–8.
 70. Halley GC, Tibby S. Hemodynamic monitoring. In: Nichols DG, editor. 
Roger’s textbook of pediatric intensive care. Philadelphia: Wolters 
Kluwer/Lippincott, Williams & Wilkins; 2008. p. 1039–63.
 71. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection 
of cardiac injury. CMAJ. 2005;173(10):1191–202.
 72. Checchia PA, Moynihan JA, Brown L. Cardiac troponin I as a 
predictor of mortality for pediatric submersion injuries requiring 
out‑of‑hospital cardiopulmonary resuscitation. Pediatr Emerg Care. 
2006;22(4):222–5.
 73. Kantor PF, Rusconi P, Lipshultz S, Mital S, Wilkinson JD, Burch M. Current 
applications and future needs for biomarkers in pediatric cardio‑
myopathy and heart failure: summary from the second international 
conference on pediatric cardiomyopathy. Prog Pediatr Cardiol. 
2011;32(1):11–4.
 74. Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu 
H, et al. The role of N‑terminal pro‑B‑type natriuretic peptide in the 
diagnosis of congestive heart failure in children—correlation with the 
heart failure score and comparison with B‑type natriuretic peptide. Circ 
J. 2010;74(5):998–1005.
 75. Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A. Prognostic 
value of plasma N‑terminal pro‑brain natriuretic peptide in children 
with congenital heart defects and open‑heart surgery. J Pediatr. 
2006;148(3):372–6.
 76. Nir A, Lindinger A, Rauh M, Bar‑Oz B, Laer S, Schwachtgen L, et al. 
NT‑pro‑B‑type natriuretic peptide in infants and children: reference 
values based on combined data from four studies. Pediatr Cardiol. 
2009;30(1):3–8.
 77. Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, et al. Amino‑
terminal pro‑brain‑type natriuretic peptide: heart or lung disease in 
pediatric respiratory distress? Pediatrics. 2005;115(5):1347–50.
 78. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt 
W. Role of brain natriuretic peptide in risk stratification of patients with 
congestive heart failure. J Am Coll Cardiol. 2001;38(7):1934–41.
 79. Pottecher J, Bouzou G, Van de Louw A. Monitorage de la saturation de 
pouls: intérêts et limites. Réanimation. 2003;12:30–6.
 80. Marino BS, Kaltman JR, Tanel RE. Cardiac conduction, dysrythmia, and 
pacing. In: Nichols DG, editor. Roger’s textbook of pediatric intensive 
care. Philadelphia: Wolters Kluwer/Lippincott, Williams & Wilkins; 2008. 
p. 1126–49.
 81. Breinholt JP, Nelson DP, Towbin JA. Heart failure in infants and children: 
cardiomyopathy. In: Nichols DG, editor. Roger’s textbook of pediatric 
intensive care. Philadelphia: Wolters Kluwer/Lippincott, Williams & 
Wilkins; 2008. p. 1082–92.
 82. Dannevig I, Dale HC, Liestol K, Lindemann R. Blood pressure in 
the neonate: three non‑invasive oscillometric pressure monitors 
compared with invasively measured blood pressure. Acta Paediatr. 
2005;94(2):191–6.
 83. Chantepie A, Gold F. Physiologie et pathologie circulatoires. In: Amiel‑
Tison C, Cabrol D, editors. Foetus et nouveau‑né de faible poids. 2ième 
ed. Masson, Paris: Collection de la périnatalité. 2000. p. 63–83.
 84. Clark JA, Lieh‑Lai MW, Sarnaik A, Mattoo TK. Discrepancies between 
direct and indirect blood pressure measurements using various recom‑
mendations for arm cuff selection. Pediatrics. 2002;110(5):920–3.
 85. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving Sepsis Campaign: international guidelines for manage‑
ment of severe sepsis and septic shock, 2012. Intensive Care Med. 
2013;39(2):165–228.
 86. Sofer S, Zucker N, Bilenko N, Levitas A, Zalzstein E, Amichay D, et al. 
The importance of early bedside echocardiography in children with 
scorpion envenomation. Toxicon. 2013;68:1–8.
 87. Joseph MX, Disney PJ, Da Costa R, Hutchison SJ. Transthoracic echo‑
cardiography to identify or exclude cardiac cause of shock. Chest. 
2004;126(5):1592–7.
 88. Pershad J, Myers S, Plouman C, Rosson C, Elam K, Wan J, et al. 
Bedside limited echocardiography by the emergency physician 
is accurate during evaluation of the critically ill patient. Pediatrics. 
2004;114(6):e667–71.
 89. Spurney CF, Sable CA, Berger JT, Martin GR. Use of a hand‑carried ultra‑
sound device by critical care physicians for the diagnosis of pericardial 
effusions, decreased cardiac function, and left ventricular enlargement 
in pediatric patients. J Am Soc Echocardiogr. 2005;18(4):313–9.
 90. Ruggiero A, De Rosa G, Rizzo D, Leo A, Maurizi P, De Nisco A, et al. 
Myocardial performance index and biochemical markers for early 
detection of doxorubicin‑induced cardiotoxicity in children with acute 
lymphoblastic leukaemia. Int J Clin Oncol. 2013;18(5):927–33.
 91. Vignon P, Mucke F, Bellec F, Marin B, Croce J, Brouqui T, et al. Basic critical 
care echocardiography: validation of a curriculum dedicated to noncar‑
diologist residents. Crit Care Med. 2011;39(4):636–42.
 92. Creteur J. Monitorage de la saturation tissulaire musculaire en oxygène 
dans les états de choc. Réanimation. 2009;18:254–60.
 93. Tobias JD, Russo P, Russo J. Changes in near infrared spectroscopy 
during deep hypothermic circulatory arrest. Ann Card Anaesth. 
2009;12(1):17–21.
 94. McQuillen PS, Nishimoto MS, Bottrell CL, Fineman LD, Hamrick SE, Glid‑
den DV, et al. Regional and central venous oxygen saturation monitor‑
ing following pediatric cardiac surgery: concordance and association 
with clinical variables. Pediatr Crit Care Med. 2007;8(2):154–60.
 95. Chakravarti SB, Mittnacht AJ, Katz JC, Nguyen K, Joashi U, Srivastava S. 
Multisite near‑infrared spectroscopy predicts elevated blood lactate 
level in children after cardiac surgery. J Cardiothorac Vasc Anesth. 
2009;23(5):663–7.
 96. Kaufman J, Almodovar MC, Zuk J, Friesen RH. Correlation of abdomi‑
nal site near‑infrared spectroscopy with gastric tonometry in infants 
following surgery for congenital heart disease. Pediatr Crit Care Med. 
2008;9(1):62–8.
 97. Abramo T, Aggarwal N, Kane I, Crossman K, Meredith M. Cerebral oxi‑
metry and cerebral blood flow monitoring in 2 pediatric survivors with 
out‑of‑hospital cardiac arrest. Am J Emerg Med. 2014;32(4):394 e5–e10.
 98. Nagdyman N, Fleck TP, Ewert P, Abdul‑Khaliq H, Redlin M, Lange PE. 
Cerebral oxygenation measured by near‑infrared spectroscopy during 
circulatory arrest and cardiopulmonary resuscitation. Br J Anaesth. 
2003;91(3):438–42.
 99. Rozé JC, Bigras JL. Surveillance cardiorespiratoire. In: Lacroix J, Gauthier 
M, Hubert P, Leclerc F, Gaudreault P, editors. Urgences et soins intensifs 
pediatriques. Masson: Edition du Sainte Justine et Elsevier; 2007. p. 
3–33.
 100. Ranucci M, Isgro G, De La Torre T, Romitti F, De Benedetti D, Carlucci 
C, et al. Continuous monitoring of central venous oxygen satura‑
tion (Pediasat) in pediatric patients undergoing cardiac surgery: a 
validation study of a new technology. J Cardiothorac Vasc Anesth. 
2008;22(6):847–52.
 101. Grissom CK, Morris AH, Lanken PN, Ancukiewicz M, Orme JF Jr, Sch‑
oenfeld DA, et al. Association of physical examination with pulmo‑
nary artery catheter parameters in acute lung injury. Crit Care Med. 
2009;37(10):2720–6.
 102. Walley KR. Use of central venous oxygen saturation to guide therapy. 
Am J Respir Crit Care Med. 2010;184:514–20.
Page 16 of 16Brissaud et al. Ann. Intensive Care  (2016) 6:14 
 103. Skowno JJ, Broadhead M. Cardiac output measurement in pediatric 
anesthesia. Paediatr Anaesth. 2008;18(11):1019–28.
 104. Sanchez O, Castelain V. Intérêt du cathétérisme cardiaque droit en 
réanimation. EMC (Elsevier Masson SAS, Paris). 2007; Pneumologie 
(6‑040‑P‑30).
 105. Lemson J, de Boode WP, Hopman JC, Singh SK, van der Hoeven JG. Vali‑
dation of transpulmonary thermodilution cardiac output measurement 
in a pediatric animal model. Pediatr Crit Care Med. 2008;9(3):313–9.
 106. Pauli C, Fakler U, Genz T, Hennig M, Lorenz HP, Hess J. Cardiac output 
determination in children: equivalence of the transpulmonary ther‑
modilution method to the direct Fick principle. Intensive Care Med. 
2002;28(7):947–52.
 107. Tibby SM, Hatherill M, Marsh MJ, Morrison G, Anderson D, Murdoch 
IA. Clinical validation of cardiac output measurements using femoral 
artery thermodilution with direct Fick in ventilated children and infants. 
Intensive Care Med. 1997;23(9):987–91.
 108. Kim JJ, Dreyer WJ, Chang AC, Breinholt JP 3rd, Grifka RG. Arterial pulse 
wave analysis: an accurate means of determining cardiac output in 
children. Pediatr Crit Care Med. 2006;7(6):532–5.
 109. del Nido PJ, Dalton HJ, Thompson AE, Siewers RD. Extracorporeal mem‑
brane oxygenator rescue in children during cardiac arrest after cardiac 
surgery. Circulation. 1992;86(5 Suppl):II300–4.
 110. Alsoufi B, Al‑Radi OO, Nazer RI, Gruenwald C, Foreman C, Williams WG, 
et al. Survival outcomes after rescue extracorporeal cardiopulmonary 
resuscitation in pediatric patients with refractory cardiac arrest. J Thorac 
Cardiovasc Surg. 2007;134(4):952–9 e2.
 111. Alsoufi B, Awan A, Manlhiot C, Guechef A, Al‑Halees Z, Al‑Ahmadi 
M, et al. Results of rapid‑response extracorporeal cardiopulmonary 
resuscitation in children with refractory cardiac arrest following cardiac 
surgery. Eur J Cardiothorac Surg. 2014;45(2):268–75.
 112. Delmo Walter EM, Alexi‑Meskishvili V, Huebler M, Redlin M, Boettcher 
W, Weng Y, et al. Rescue extracorporeal membrane oxygenation in 
children with refractory cardiac arrest. Interact CardioVasc Thorac Surg. 
2011;12(6):929–34.
 113. Duncan BW, Ibrahim AE, Hraska V, del Nido PJ, Laussen PC, Wessel DL, 
et al. Use of rapid‑deployment extracorporeal membrane oxygena‑
tion for the resuscitation of pediatric patients with heart disease after 
cardiac arrest. J Thorac Cardiovasc Surg. 1998;116(2):305–11.
 114. Huang SC, Wu ET, Wang CC, Chen YS, Chang CI, Chiu IS, et al. Eleven 
years of experience with extracorporeal cardiopulmonary resuscitation 
for paediatric patients with in‑hospital cardiac arrest. Resuscitation. 
2012;83(6):710–4.
 115. Lowry AW, Morales DL, Graves DE, Knudson JD, Shamszad P, Mott AR, 
et al. Characterization of extracorporeal membrane oxygenation for 
pediatric cardiac arrest in the United States: analysis of the kids’ inpa‑
tient database. Pediatr Cardiol. 2013;34(6):1422–30.
 116. Matos RI, Watson RS, Nadkarni VM, Huang HH, Berg RA, Meaney PA, 
et al. Duration of cardiopulmonary resuscitation and illness category 
impact survival and neurologic outcomes for in‑hospital pediatric 
cardiac arrests. Circulation. 2013;127(4):442–51.
 117. Ortmann L, Prodhan P, Gossett J, Schexnayder S, Berg R, Nadkarni V, 
et al. Outcomes after in‑hospital cardiac arrest in children with cardiac 
disease: a report from Get With the Guidelines‑Resuscitation. Circula‑
tion. 2011;124(21):2329–37.
 118. Prodhan P, Fiser RT, Dyamenahalli U, Gossett J, Imamura M, Jaquiss RD, 
et al. Outcomes after extracorporeal cardiopulmonary resuscitation 
(ECPR) following refractory pediatric cardiac arrest in the intensive care 
unit. Resuscitation. 2009;80(10):1124–9.
 119. Raymond TT, Cunnyngham CB, Thompson MT, Thomas JA, Dalton HJ, 
Nadkarni VM. Outcomes among neonates, infants, and children after 
extracorporeal cardiopulmonary resuscitation for refractory in hospital 
pediatric cardiac arrest: a report from the National Registry of Cardio‑
pulmonary Resuscitation. Pediatr Crit Care Med. 2010;11(3):362–71.
 120. Turek JW, Andersen ND, Lawson DS, Bonadonna D, Turley RS, Peters MA, 
et al. Outcomes before and after implementation of a pediatric rapid‑
response extracorporeal membrane oxygenation program. Ann Thorac 
Surg. 2013;95(6):2140–6 (discussion 6–7).
 121. Brown KL, Ichord R, Marino BS, Thiagarajan RR. Outcomes following 
extracorporeal membrane oxygenation in children with cardiac disease. 
Pediatr Crit Care Med. 2013;14(5 Suppl 1):S73–83.
 122. Coskun KO, Coskun ST, Popov AF, Hinz J, El‑Arousy M, Schmitto JD, et al. 
Extracorporeal life support in pediatric cardiac dysfunction. J Cardio‑
thorac Surg. 2010;5:112.
 123. Duncan BW, Bohn DJ, Atz AM, French JW, Laussen PC, Wessel DL. 
Mechanical circulatory support for the treatment of children with acute 
fulminant myocarditis. J Thorac Cardiovasc Surg. 2001;122(3):440–8.
 124. Wilmot I, Morales DL, Price JF, Rossano JW, Kim JJ, Decker JA, et al. 
Effectiveness of mechanical circulatory support in children with acute 
fulminant and persistent myocarditis. J Card Fail. 2011;17(6):487–94.
 125. Lequier L, Joffe AR, Robertson CM, Dinu IA, Wongswadiwat Y, Anton 
NR, et al. Two‑year survival, mental, and motor outcomes after cardiac 
extracorporeal life support at less than five years of age. J Thorac Car‑
diovasc Surg. 2008;136(4):976–83 e3.
 126. Kleinman ME, de Caen AR, Chameides L, Atkins DL, Berg RA, Berg MD, 
et al. Part 10: pediatric basic and advanced life support: 2010 interna‑
tional consensus on cardiopulmonary resuscitation and emergency 
cardiovascular care science with treatment recommendations. Circula‑
tion. 2010;122(16 Suppl 2):S466–515.
 127. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH, Bratton SL. Extracor‑
poreal membrane oxygenation to aid cardiopulmonary resuscitation in 
infants and children. Circulation. 2007;116(15):1693–700.
 128. Tajik M, Cardarelli MG. Extracorporeal membrane oxygenation after 
cardiac arrest in children: what do we know? Eur J Cardiothorac Surg. 
2008;33(3):409–17.
 129. Haile DT, Schears GJ. Optimal time for initiating extracorpor‑
eal membrane oxygenation. Semin Cardiothorac Vasc Anesth. 
2009;13(3):146–53.
 130. Barrett CS, Bratton SL, Salvin JW, Laussen PC, Rycus PT, Thiagarajan RR. 
Neurological injury after extracorporeal membrane oxygenation use 
to aid pediatric cardiopulmonary resuscitation. Pediatr Crit Care Med. 
2009;10(4):445–51.
 131. Huang SC, Wu ET, Chen YS, Chang CI, Chiu IS, Wang SS, et al. Extracor‑
poreal membrane oxygenation rescue for cardiopulmonary resuscita‑
tion in pediatric patients. Crit Care Med. 2008;36(5):1607–13.
 132. Trittenwein G, Pansi H, Graf B, Golej J, Burda G, Hermon M, et al. 
Proposed entry criteria for postoperative cardiac extracorporeal mem‑
brane oxygenation after pediatric open heart surgery. Artif Organs. 
1999;23(11):1010–4.
 133. Karamlou T, Vafaeezadeh M, Parrish AM, Cohen GA, Welke KF, Permut 
L, et al. Increased extracorporeal membrane oxygenation center case 
volume is associated with improved extracorporeal membrane oxy‑
genation survival among pediatric patients. J Thorac Cardiovasc Surg. 
2013;145(2):470–5.
